UY23327A1 - Proceso para la preparacion de muteina humana del factor de necrosis tumoral - Google Patents
Proceso para la preparacion de muteina humana del factor de necrosis tumoralInfo
- Publication number
- UY23327A1 UY23327A1 UY23327A UY23327A UY23327A1 UY 23327 A1 UY23327 A1 UY 23327A1 UY 23327 A UY23327 A UY 23327A UY 23327 A UY23327 A UY 23327A UY 23327 A1 UY23327 A1 UY 23327A1
- Authority
- UY
- Uruguay
- Prior art keywords
- necrosis factor
- tumor necrosis
- human
- mutein
- preparation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Es objeto de la presente invención el proporcionar una muteína del factor de necrosis tumoral humano o una sal farmacéutica aceptable de la misma, caracterizada porque la secuencia de TNF está cambiada por delección, inserción y/o sustitución de uno o mas aminoácidos de forma que la muteína presenta una diferencia significativa entre su afinidad para la unión con el receptor del factor de necrosis tumoral p75 humano y el receptor del factor de necrosis tumoral p55 humano, secuencias de ADN que codifican dichas muteínas, vectores que comprenden dichas secuencias de ADN, células hospedadoras transformadas con dichos vectores y un procedimiento para la producción de dichas muteínas.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP90810901 | 1990-11-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY23327A1 true UY23327A1 (es) | 1992-05-19 |
Family
ID=8205969
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY23327A UY23327A1 (es) | 1990-11-21 | 1991-11-19 | Proceso para la preparacion de muteina humana del factor de necrosis tumoral |
Country Status (17)
Country | Link |
---|---|
US (2) | US5422104A (es) |
EP (1) | EP0486908A3 (es) |
JP (1) | JPH06256395A (es) |
AR (1) | AR245783A1 (es) |
AU (1) | AU655948B2 (es) |
CA (1) | CA2055168A1 (es) |
FI (1) | FI915379A (es) |
HU (1) | HUT62034A (es) |
IE (1) | IE914035A1 (es) |
IL (1) | IL100062A0 (es) |
MC (1) | MC2300A1 (es) |
MX (1) | MX9102110A (es) |
NO (1) | NO914541L (es) |
NZ (1) | NZ240595A (es) |
PT (1) | PT99560A (es) |
UY (1) | UY23327A1 (es) |
ZA (1) | ZA919035B (es) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SK376492A3 (en) * | 1992-04-02 | 1995-06-07 | Hoffmann La Roche | Tnf - muteins and method of their production |
CA2119089A1 (en) * | 1993-03-29 | 1994-09-30 | David Banner | Tumor necrosis factor muteins |
US7070771B1 (en) | 1996-12-09 | 2006-07-04 | Regents Of The University Of California | Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells |
EP1069917A4 (en) * | 1998-03-20 | 2005-02-09 | Genzyme Corp | NEW COMPLEMENTARY PAIRS OF RECEPTORS / LIGANDS AND ADOPTIVE IMMUNOTHERAPY USING THE SAME |
ATE329610T1 (de) * | 2000-02-16 | 2006-07-15 | Genentech Inc | Anti-april antikörper und hybridomazellen |
US7687461B2 (en) * | 2000-03-02 | 2010-03-30 | Xencor, Inc. | Treatment of TNF-α related disorders with TNF-α variant proteins |
US7446174B2 (en) | 2001-03-02 | 2008-11-04 | Xencor, Inc. | Protein based TNF-α variants for the treatment of TNF-α related disorders |
US7101974B2 (en) | 2000-03-02 | 2006-09-05 | Xencor | TNF-αvariants |
US7056695B2 (en) | 2000-03-02 | 2006-06-06 | Xencor | TNF-α variants |
US7662367B2 (en) | 2000-03-02 | 2010-02-16 | Xencor, Inc. | Pharmaceutical compositions for the treatment of TNF-α related disorders |
US7244823B2 (en) | 2000-03-02 | 2007-07-17 | Xencor | TNF-alpha variants proteins for the treatment of TNF-alpha related disorders |
US20070172449A1 (en) * | 2000-03-02 | 2007-07-26 | Xencor, Inc. | TNF-alpha VARIANT FORMULATIONS FOR THE TREATMENT OF TNF-alpha RELATED DISORDERS |
US6579522B1 (en) | 2000-06-27 | 2003-06-17 | Genvec, Inc. | Replication deficient adenoviral TNF vector |
US20050070689A1 (en) * | 2001-08-03 | 2005-03-31 | Genentech, Inc. | Taci and br3 polypeptides and uses thereof |
US20030086903A1 (en) * | 2001-11-02 | 2003-05-08 | Genvec, Inc. | Therapeutic regimen for treating cancer |
US7786282B2 (en) * | 2001-12-06 | 2010-08-31 | The Regents Of The University Of California | Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain |
WO2004011611A2 (en) * | 2002-07-25 | 2004-02-05 | Genentech, Inc. | Taci antibodies and uses thereof |
US7285269B2 (en) * | 2002-12-02 | 2007-10-23 | Amgen Fremont, Inc. | Antibodies directed to tumor necrosis factor |
CA2526402A1 (en) * | 2003-06-05 | 2005-01-20 | Genentech, Inc. | Blys antagonists and uses thereof |
US20050163775A1 (en) * | 2003-06-05 | 2005-07-28 | Genentech, Inc. | Combination therapy for B cell disorders |
EP1687032B1 (en) * | 2003-11-14 | 2010-02-24 | Genvec, Inc. | Pharmaceutical composition for treating unresectable, locally advanced pancreatic cancer (lapc). |
TW200526780A (en) * | 2004-01-06 | 2005-08-16 | Hayashibara Biochem Lab | TNF antagonists and TNF inhibitors comprising the same as the active ingredient |
EP1598075A1 (en) * | 2004-05-21 | 2005-11-23 | LEK Pharmaceuticals d.d. | Process for the isolation and / or purification of proteins |
GB0425972D0 (en) | 2004-11-25 | 2004-12-29 | Celltech R&D Ltd | Biological products |
JP2008526889A (ja) * | 2005-01-10 | 2008-07-24 | リサーチ ディベロップメント ファウンデーション | 癌治療のための標的化キメラ分子 |
CA2629306A1 (en) * | 2005-11-23 | 2007-05-31 | Genentech, Inc. | Methods and compositions related to b cell assays |
WO2008127515A1 (en) * | 2007-03-01 | 2008-10-23 | Cytologic, Inc. | Compositions and method for enhancing immune responses in mammals |
US11535673B2 (en) * | 2007-04-05 | 2022-12-27 | President and Fellows of Harvard CoHege | Chimeric activators: quantitatively designed protein therapeutics and uses thereof |
US9605844B2 (en) * | 2009-09-01 | 2017-03-28 | Cree, Inc. | Lighting device with heat dissipation elements |
WO2014124134A1 (en) | 2013-02-07 | 2014-08-14 | The General Hospital Corporation | Methods for expansion or depletion of t-regulatory cells |
EP3139955B1 (en) | 2014-04-30 | 2024-03-20 | President and Fellows of Harvard College | Fusion proteins for treating cancer and related methods |
MX2019005242A (es) | 2016-11-09 | 2019-09-10 | Philogen Spa | Inmunoconjugados mutantes de interleucina-2 y de factor de necrosis tumoral. |
AU2021332460A1 (en) | 2020-08-27 | 2023-04-06 | Enosi Therapeutics Corporation | Methods and compositions to treat autoimmune diseases and cancer |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4650674A (en) * | 1984-07-05 | 1987-03-17 | Genentech, Inc. | Synergistic cytotoxic composition |
GR851626B (es) * | 1984-07-05 | 1985-11-26 | Genentech Inc | |
EP0251037B1 (en) * | 1986-06-20 | 1994-06-15 | Dainippon Pharmaceutical Co., Ltd. | Novel human TNF polypeptide mutants and DNAs encoding said mutants |
JPH07106158B2 (ja) * | 1986-12-04 | 1995-11-15 | サントリー株式会社 | 抗腫瘍活性を有する新規ポリペプチドおよびその製造法 |
WO1988006625A2 (en) * | 1987-02-26 | 1988-09-07 | Cetus Corporation | Arginine-depleted human tumor necrosis factor |
JPS63291590A (ja) * | 1987-05-25 | 1988-11-29 | Teijin Ltd | 新規生理活性ポリペプチド |
DE3843534A1 (de) * | 1988-12-23 | 1990-07-12 | Basf Ag | Neue tnf-polypeptide |
-
1991
- 1991-11-08 CA CA002055168A patent/CA2055168A1/en not_active Abandoned
- 1991-11-11 EP EP19910119128 patent/EP0486908A3/en not_active Withdrawn
- 1991-11-14 NZ NZ240595A patent/NZ240595A/en unknown
- 1991-11-14 FI FI915379A patent/FI915379A/fi not_active Application Discontinuation
- 1991-11-14 ZA ZA919035A patent/ZA919035B/xx unknown
- 1991-11-15 IL IL100062A patent/IL100062A0/xx unknown
- 1991-11-15 AU AU87915/91A patent/AU655948B2/en not_active Ceased
- 1991-11-15 JP JP3300863A patent/JPH06256395A/ja active Pending
- 1991-11-18 MX MX9102110A patent/MX9102110A/es unknown
- 1991-11-18 MC MC912217A patent/MC2300A1/xx unknown
- 1991-11-18 HU HU913595A patent/HUT62034A/hu unknown
- 1991-11-19 AR AR91321196A patent/AR245783A1/es active
- 1991-11-19 UY UY23327A patent/UY23327A1/es not_active IP Right Cessation
- 1991-11-20 NO NO91914541A patent/NO914541L/no unknown
- 1991-11-20 US US07/794,400 patent/US5422104A/en not_active Expired - Fee Related
- 1991-11-20 PT PT99560A patent/PT99560A/pt not_active Application Discontinuation
- 1991-11-20 IE IE403591A patent/IE914035A1/en not_active Application Discontinuation
-
1995
- 1995-03-01 US US08/397,470 patent/US5652353A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
IE914035A1 (en) | 1992-06-03 |
EP0486908A3 (en) | 1992-11-19 |
AU655948B2 (en) | 1995-01-19 |
HU913595D0 (en) | 1992-01-28 |
US5422104A (en) | 1995-06-06 |
IL100062A0 (en) | 1992-08-18 |
JPH06256395A (ja) | 1994-09-13 |
FI915379A (fi) | 1992-05-22 |
CA2055168A1 (en) | 1992-05-22 |
ZA919035B (en) | 1992-08-26 |
NZ240595A (en) | 1994-09-27 |
AU8791591A (en) | 1992-05-28 |
NO914541L (no) | 1992-05-22 |
US5652353A (en) | 1997-07-29 |
HUT62034A (en) | 1993-03-29 |
AR245783A1 (es) | 1994-02-28 |
EP0486908A2 (en) | 1992-05-27 |
MX9102110A (es) | 1992-07-08 |
MC2300A1 (fr) | 1993-09-06 |
NO914541D0 (no) | 1991-11-20 |
PT99560A (pt) | 1992-10-30 |
FI915379A0 (fi) | 1991-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY23327A1 (es) | Proceso para la preparacion de muteina humana del factor de necrosis tumoral | |
MY101887A (en) | A novel human physiologically active polypeptide. | |
BG64881B2 (en) | TNF-BINDING PROTEINS | |
MX9301700A (es) | Muteinas del factor de necrosis tumoral humano, procedimiento para su preparacion y composiciones farmaceuticas que las contienen. | |
PT93910A (pt) | Prodesso para a preparacao de uma proteina heterologa mediante secrecao a partir de uma celula | |
SG47766A1 (en) | CD2-binding domain of lymphocyte function associated antigen 3 | |
KR890003802A (ko) | 재조합 dna 기술에 의해 제조된 소의 췌장 트립신 억제제, 그 제조 방법, 발현 벡터 및 재조합 숙주 및 그의 제약적 용도 | |
DE69738370D1 (de) | Modulatoren des tnf-rezeptor-assoziierten faktors, deren herstellung und verwendungen | |
Goth et al. | Aspartic acid 50 and tyrosine 108 are essential for receptor binding and cytotoxic activity of tumour necrosis factor beta (lymphotoxin) | |
IT1247165B (it) | Uso terapeutico della fosfatidilserina e derivati in patologie degenerative anche associate a disfunsioni immunitarie. | |
NO20011460L (no) | Cytokinreseptor zalphall | |
MX9203138A (es) | Dominio de enlace cd2-de antigeno 3 (lfa-3) asociado con funcion linfositos. | |
YU199691A (sh) | Receptor za humani interleukin-5 | |
EP0369816A3 (en) | Monoclonal antibodies specific for human polymorphic epithelial mucin | |
ATE508194T1 (de) | Neue cytokinine aus vögeln und dafür codierende genetische sequenzen | |
NO983238L (no) | Exodus kjemokin materialer og fremgangsmÕter | |
EA200100395A1 (ru) | Фармацевтическая композиция, содержащая фрагменты днк, кодирующей антигенный белок, обладающая противоопухолевым действием | |
DK0421949T3 (da) | Kemisk modificerede allergener og fremgangsmåde til deres fremstilling | |
NZ505827A (en) | Concatamers of non-identical genes for the same polypeptide and their application in vaccines | |
NO890174L (no) | Rekombinante interleukin-1alfa-polypeptider. | |
DE68905097D1 (de) | Peptid-molekuele, wirksam gegen gram-positive keime. | |
YU182791A (sh) | Tnf-muteini | |
Palladino Jr et al. | Immunopharmacology of tumor necrosis factors α and β | |
DK0540560T3 (da) | Ancrod-lignende proteiner, fremstilling og anvendelse deraf | |
BR0012740A (pt) | Compostos para tratamento de distúrbios do sistema infeccioso e imune e métodos para seu emprego |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
VENC | Patent expired |
Effective date: 20110123 |